25 results
8-K
EX-99.1
VINC
Vincerx Pharma Inc
12 Aug 21
Vincerx Pharma Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
4:19pm
lymphoma” at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
Published an article entitled “Changing for the Better: Discovery
8-K
EX-99.1
VINC
Vincerx Pharma Inc
12 Nov 21
Vincerx Pharma Reports Third Quarter 2021 Financial Results and Provides a
6:16am
with advanced solid tumors. Other combinations studies are in planning.
Announced upcoming presentations at the 63rd American Society of Hematology (ASH) Annual
8-K
EX-99.1
VINC
Vincerx Pharma Inc
17 May 21
Vincerx Pharma Reports First Quarter 2021 Financial Results
4:02pm
with double-hit lymphoma will be presented at the 2021 American Society of Clinical Oncology Annual Meeting
Announced formation of Scientific
8-K
EX-99.2
VINC
Vincerx Pharma Inc
29 Sep 20
LifeSci Acquisition Corp. Announces Merger
8:32am
) D Warren Brown Chair of Leukemia Research at OSU, Comprehensive Cancer Center CMO, Beat AML LLC, Leukemia & Lymphoma Society
Management Team … 2012;30: 3460-67 Copyright © 2012 by American Society of Clinical Oncology Double-hit (DH)-DLBCL Activation of MYC and BCL2/BCL6 genes Rearrangements
DEFA14A
EX-99.2
VINC
Vincerx Pharma Inc
29 Sep 20
Additional proxy soliciting materials
8:30am
) D Warren Brown Chair of Leukemia Research at OSU, Comprehensive Cancer Center CMO, Beat AML LLC, Leukemia & Lymphoma Society
Management Team … 2012;30: 3460-67 Copyright © 2012 by American Society of Clinical Oncology Double-hit (DH)-DLBCL Activation of MYC and BCL2/BCL6 genes Rearrangements
8-K
EX-99.1
mv7bbcy1a8q4rym7zog
10 Nov 22
Vincerx Pharma Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
4:27pm
8-K
EX-99.1
zw6tugnjutjkxi0b
11 May 23
Vincerx Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:02pm
8-K
EX-99.1
g7l5c9ma
29 Mar 22
Vincerx Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
8:06am
8-K
EX-99.1
5kasrwujmay
14 Nov 23
Vincerx Pharma Reports Third Quarter 2023 Financial Results
12:00am
10-K
xvwxr6u8
23 Sep 20
Annual report
3:07pm
DRS/A
vdhe5umy435bmed9
13 Jan 20
Draft registration statement (amended)
12:00am
DRS
an2uzwhf08sig1i
12 Dec 19
Draft registration statement
12:00am
S-1
nbguw6afvng0m
14 Feb 20
IPO registration
5:11pm
424B4
o1bqbq
9 Mar 20
Prospectus supplement with pricing info
4:39pm
424B3
vxetmxdcqyag8yl
26 Oct 21
Prospectus supplement
8:39am